Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of subcutaneous Tadekinig alfa in adult-onset Still's disease
2014-002500-24Phase 2Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tadekinig alfa in adult-onset Still's disease (AOSD), sponsored by AB2 Bio Ltd. Primary endpoint: Safety and tolerability endpoints. Started Oct 2014; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on 2014-002500-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002500-24.